








FY2020 Results Presentation



Disclaimer

This presentation does not constitute, or form any part of any offer for sale or subscription of, or solicitation of any offer to buy or subscribe for, any securities in Cordlife Group Limited (“Cordlife”) in Singapore or any other jurisdiction nor shall it or any part of it form the basis of, or be relied on in connection with, any investment decision, contract or commitment whatsoever in this or any jurisdiction. This presentation may contain forward-looking statements that involve assumptions, risks and uncertainties. Actual future performance, outcomes and results may differ materially from those expressed in forward-looking statements as a result of a number of risks, uncertainties and assumptions. You are cautioned not to place undue reliance on these forward-looking statements, if any, which are based on the current view of management on future events. The information contained in this presentation has not been independently verified. No representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Neither Cordlife or any of its affiliates, advisers or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising, whether directly or indirectly, from any use, reliance or distribution of this presentation or its contents or otherwise arising in connection with this presentation. The past performance of Cordlife is not indicative future performance. The value of shares in Cordlife (“Shares”) and the income derived from them may fall as well as rise. Shares are not obligations of, deposits in, or guaranteed by, Cordlife or any of its affiliates. An investment in Shares is subject to investment risks, including the possible loss of the principal amount invested.

Content


-  Overview
-  Financial Highlights
-  Outlook
-  Growth Strategies

Overview

cordlife







Business Overview – Operating Segments



BANKING
DIAGNOSTICS
DIGITAL HEALTHCARE
OTHERS

Business Overview – Market Presence



-  Cordlife's Headquarters
-  Cordlife's Subsidiaries
-  Cordlife's Associate
-  Cordlife's Marketing Agents

BANKING
DIAGNOSTICS
DIGITAL HEALTHCARE
OTHERS

Our Network

Cordlife owns the largest network of cord blood banks in Asia with full stem cell banking facilities in six key markets namely Singapore, Hong Kong, Indonesia, India, Malaysia and the Philippines.

The Group is among the leading private cord blood banks in these key markets.

Financial Highlights

cordlife



FY2020 Results Summary

REVENUE

S\$50.6 million

(17.8)% y-o-y

GROSS PROFIT

S\$31.7 million

(20.0)% y-o-y

GP MARGIN

62.7%

(1.8) pp y-o-y

NET PROFIT

S\$6.6 million

+1.4 % y-o-y

NET PROFIT MARGIN

12.9%

+2.4 pp y-o-y

NET CASH¹

S\$71.2 million

+S\$21.5 million from 31 Dec 2019

a. Includes cash and cash equivalents, fixed deposits and short-term investments less interest-bearing borrowings (current and non-current)

Analysis of FY2020

Revenue


- The Group's revenue decreased 17.8% yoy to S\$50.6 million.
- This was due to lower new samples processed and stored in all markets as a result of ongoing COVID-19 pandemic.
- However, this was buffered by higher revenue contribution from diagnostics services and higher take-up of higher-priced plans in the Philippines and Singapore market.

Net Profit

- Net profit after tax grew 1.4% yoy to S\$6.6 million, mainly driven by
 - i. government relief measures for COVID-19 given in Singapore and Hong Kong of an aggregate of \$2.1 million recognised this quarter ("Covid-19 Government Grants")¹,
 - ii. lower marketing expenses (attributable to lower advertising and promotion expenses due to restrictions on physical trade fairs and antenatal seminars as a result of the outbreak of COVID-19),
 - iii. lower administrative expenses (due to lower staff costs and lower travel costs, partially offset by an increase in impairment loss on trade receivables),
 - iv. lower tax expense, contributed partly by reversal of over-provision of tax for prior years.

¹Without the Covid-19 Government Grants, net profit after tax would have amounted to S\$4.4 million approximately, which represents a 31.4% yoy decrease.


Financials – Revenue



* Prepared in accordance with FRS18 – *Revenue*.

Prepared in accordance with SFRS(I) 15 – *Revenue from Contracts with Customers*.


Financials – Gross Profit



* Prepared in accordance with FRS18 – *Revenue*.

Prepared in accordance with SFRS(I) 15 – *Revenue from Contracts with Customers*.

Financials – Operating profit after tax



^ Without the Covid-19 Government Grants, net profit after tax and net profit margin would have amounted to S\$4.4 million and 8.8% respectively.

* Prepared in accordance with FRS18 – *Revenue*.

Prepared in accordance with SFRS(I) 15 – *Revenue from Contracts with Customers*.

Financials – Balance Sheet

S\$' mil	As at 31 Dec 2020	As at 31 Dec 2019
Net Assets	133.2	129.3
Borrowings	4.0	4.3
Gearing ₁ (%)	3.0	3.3
Cash & Cash Equivalents, Fixed Deposits and Short-term Investments	75.2	54.0
Net Asset Value Per Share (SG cents)	52.33	50.89

1: Total Borrowings/Total Equity

Financials – Cash Flow

S\$' mil	For the period ended 31 Dec 2020	For the period ended 31 Dec 2019
Net cash generated from operating activities	15.9	11.6
Net cash (used)/generated from investing activities	(1.3)	4.9
Net cash used in financing activities	(2.9)	(12.1)
Cash & cash equivalents at end of the financial period	25.9	14.8

Outlook

cordlife



Outlook

Impact of COVID-19

Business Outlook

- Revenue from banking services is recognised upon service delivery when customers give birth and store their samples and customers typically sign up a few months prior to delivery.
- The COVID-19 situation has generally resulted in the tapering of new customer sign-ups for banking services in FY2020, and this revenue trend may continue in the coming year.
- Recurring waves of the outbreak in some of the countries that the Group operates in could possibly result in the continued imposition of border and movement restrictions, causing uncertainties in demand for the Group's services in the coming months.
- The availability of the vaccines and the speed of vaccination remain a concern in some of the countries that the Group operates in.
- The Group will continue to deepen its digital capabilities and will monitor the situation closely and respond accordingly.

Group Initiatives

- Continue to refine and improve e-enrolment and online counselling process.
- Where physical seminars/antenatal classes can be held, safe distancing and hygiene practices are strictly abided by to safeguard customers' and staff's wellbeing.
- Continue to hold webinars to reach a wider audience and to educate prospective customers.

Growth Strategies

Growth Strategies

Organic Growth

- To increase penetration rate/market share
- To increase product scope
- Open new markets
- To facilitate development of stem cell ecosystem
- To create new engines of growth

M&A

- Synergistic with current business
- Earnings-accretive
- Targeting Asia

**Thank
you**

